Madrigal Pharmaceuticals, Inc. Common Stock
MDGL
$434.24
-4.21%
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, and liver cancer. Its lead asset, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist and represents the company's first commercial product, positioning Madrigal as the pioneer in a large, previously untreatable chronic liver disease market. The investor narrative has shifted decisively from clinical-stage binary risk to commercial execution: Rezdiffra's launch trajectory, payer access, and prescriber adoption now drive the stock, with quarterly revenue scaling rapidly (Q2 2026 revenue of $364 million, up 71% year-over-year) even as the company remains loss-making. Debate centers on the durability of the MASH opportunity against emerging competition, the path to profitability as R&D and SG&A spending ramp, and whether the recent share-price weakness reflects a temporary sentiment dislocation or a re-rating of long-term growth expectations.…
MDGL
Madrigal Pharmaceuticals, Inc. Common Stock
$434.24
Related headlines
Investment Opinion: Should I buy MDGL Today?
Rating: Hold. The core thesis is that Madrigal's Rezdiffra is delivering exceptional revenue growth (71% YoY) and the analyst consensus is overwhelmingly positive (18 analysts, 'strong_buy', average target $685.78 implying 52.5% upside), but the stock's severe downtrend (-24.27% YTD) and premium valuation (13.63x PS, 46.73x forward PE) warrant caution until commercial execution proves sustainable. The risk/reward is balanced but not compelling enough for a Buy given the negative momentum and cash burn.
Supporting evidence: Revenue grew 71.2% YoY to $364.25 million in Q2 2026, with sequential growth of 17.0%; gross margin is high at 89.0%; operating cash flow turned positive at $23.33 million in Q2 2026; and the forward PE of 46.73x is supported by a PEG ratio of 1.10, suggesting growth-adjusted valuation is reasonable. However, the company remains unprofitable (net loss -$57.94 million) and free cash flow is negative (-$206.29 million TTM), while the stock trades at a premium to typical commercial-stage biotech peers on PS.
Risks and conditions: The biggest risks are a slowdown in Rezdiffra adoption, gross margin compression (already from 93.7% to 89.0% over three quarters), and competitive threats in MASH. This Hold would upgrade to Buy if the stock stabilizes above $500 and revenue growth sustains above 50% YoY with positive operating cash flow for two consecutive quarters. It would downgrade to Sell if revenue growth decelerates below 30% YoY or if gross margin falls below 85%. Valuation verdict: fairly valued relative to growth prospects, but with a premium that requires flawless execution.
Sign up to view all
MDGL 12-Month Price Forecast
Madrigal presents a compelling growth story with Rezdiffra's rapid revenue ramp and a strong analyst consensus, but the stock's severe underperformance and premium valuation create a balanced risk/reward. The key tension is whether the commercial launch can sustain its trajectory to justify the forward earnings expectations. I would upgrade to bullish if the stock stabilizes above $500 and revenue growth remains above 50% YoY with positive operating cash flow. I would downgrade to bearish if revenue growth decelerates below 30% YoY or if gross margin falls below 85%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Madrigal Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $685.22 and implied upside of +57.8% versus the current price.
Average Target
$685.22
0 analysts
Implied Upside
+57.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$533 - $962
Analyst target range
Coverage is robust, with 18 analysts and a consensus recommendation of "strong_buy" (mean rating of 1.26 on a 1-5 scale where 1 is a strong buy). The average target price of $685.78 implies roughly +52.5% upside from the current $449.74, a strikingly bullish signal given the stock's recent weakness. The consensus clearly leans bullish, and the gap between the market price and the average target suggests analysts view the selloff as disconnected from fundamental progress.
The target range is wide, from a low of $543.00 (still +20.7% above the current price) to a high of $962.00 (+113.9%), signaling meaningful dispersion in assumptions about MASH penetration and profitability timing. Notably, even the lowest target sits above the current price, implying that no covering analyst models a bear case at today's valuation. Recent institutional actions skew positive: Wolfe Research upgraded to Outperform from Peer Perform on August 4, 2026, while Barclays, Canaccord, Truist, Evercore ISI, and HC Wainwright maintained Buy/Overweight ratings; B of A remains Neutral, the lone visible hold. The wide spread and unanimous above-market targets indicate high conviction in the long-term thesis but also elevated uncertainty around execution timing, which is typical for a single-product commercial-stage biotech in a large, evolving indication.
Drowning in data?
Find the real signal!
Bulls vs Bears: MDGL Investment Factors
The bull case rests on Rezdiffra's impressive 71% YoY revenue growth, a strong analyst consensus (18 analysts, 'strong_buy', average target $685.78 implying 52.5% upside), and an emerging path to profitability with positive operating cash flow in Q2 2026. However, the bear case is equally compelling: the stock is in a severe downtrend (-24.27% YTD, -15.0% in one month), remains unprofitable with negative free cash flow, and trades at a premium valuation (13.63x PS, 46.73x forward PE) that leaves little room for error. The most important tension is whether the commercial ramp can continue at a pace that justifies the forward earnings expectations, or whether decelerating growth and margin compression will force a re-rating. Currently, the bear evidence (price action, valuation, cash burn) appears stronger in the near term, but the bull case has substantial fundamental support from revenue growth and analyst conviction.
Bullish
- Rezdiffra revenue scaling rapidly: Q2 2026 revenue reached $364.25 million, up 71.2% year-over-year from $212.80 million, with sequential growth of 17.0% from Q1 2026. The multi-quarter trajectory from $287.27 million in Q3 2025 to $364.25 million in Q2 2026 demonstrates strong commercial execution in the MASH launch.
- Analyst consensus strongly bullish: 18 analysts rate the stock a 'strong_buy' with a mean rating of 1.26, and the average target price of $685.78 implies 52.5% upside from the current $449.74. Even the lowest target of $543.00 is 20.7% above the current price, indicating no analyst models a bear case at today's valuation.
- Path to profitability emerging: Net loss narrowed to -$57.94 million in Q2 2026 from -$94.39 million in Q1 2026 and -$114.19 million in Q3 2025, while operating cash flow turned positive at $23.33 million in Q2 2026 versus -$167.44 million in Q1 2026. This inflection suggests the company is approaching sustainable cash generation.
- Exceptional gross margins: Gross margin remains very high at 89.0% in Q2 2026, consistent with a specialty pharmaceutical cost structure. This provides substantial operating leverage as revenue scales and SG&A ($289.38 million) and R&D ($91.18 million) are absorbed.
Bearish
- Severe stock downtrend and underperformance: The stock is down 24.27% year-to-date versus a +11.93% gain for SPY, with a one-month decline of 15.0% and three-month decline of 18.7%. It sits at just 25.3% of its 52-week range (low $393.61, high $615.00), signaling persistent distribution and negative momentum.
- Still unprofitable with negative cash flow: Despite revenue growth, Q2 2026 net income was -$57.94 million (EPS -$1.99) and trailing twelve-month free cash flow is -$206.29 million. ROE of -47.83% and ROA of -17.84% confirm the company is consuming capital, and profitability depends on continued rapid revenue scaling.
- Premium valuation leaves little room for error: The price-to-sales ratio of 13.63x and price-to-book of 21.68x are elevated for a commercial-stage biotech, while the forward PE of 46.73x prices in a dramatic swing to profitability (estimated EPS of $55.99). Any execution misstep could trigger multiple compression.
- Gross margin compression trend: Gross margin declined from 93.7% in Q3 2025 to 91.4% in Q1 2026 and 89.0% in Q2 2026, a sequential compression that warrants monitoring as a potential signal of pricing pressure or rising cost of goods.
MDGL Technical Analysis
Madrigal is in a sustained downtrend despite a modestly positive one-year return of +1.72%, with the current price of $449.74 sitting at just 25.3% of its 52-week range (low $393.61, high $615.00). That positioning near the bottom of the annual range signals persistent distribution and a lack of buyers rather than a value opportunity being aggressively accumulated, and the year-to-date decline of -24.27% versus a +11.93% gain for SPY underscores severe relative underperformance. The stock has given back nearly all of its twelve-month gains and is testing territory that, if breached, would mark a fresh 52-week low.
Short-term momentum is clearly negative and deteriorating: the one-month change of -15.00% and three-month change of -18.74% are both worse than the six-month decline of -15.47%, indicating the selling pressure is accelerating rather than stabilizing. Relative strength readings confirm the divergence from the broader market, with a one-month relative strength of -16.22% and a three-month figure of -21.43% against a rising SPY. The most recent sessions show a sharp leg lower from roughly $517 on September 28 to $449.74 on October 16, a decline of about 13% in under three weeks, suggesting momentum traders are in control and mean-reversion bounces have been sold.
Key technical support sits at the 52-week low of $393.61, roughly 12.5% below the current price; a breakdown there would likely trigger momentum-driven selling and open a deeper air pocket. Resistance is defined by the 52-week high of $615.00, some 36.7% above current levels, with intermediate supply clustered in the $500-$540 zone where the stock repeatedly failed in September. The reported beta of -1.052 is unusual and implies the stock has historically moved inversely to the market, which complicates traditional hedging and position-sizing assumptions; combined with a maximum drawdown of -29.36%, this points to a high-risk, event-sensitive profile where volatility is driven by company-specific catalysts rather than broad market beta.
Beta
-1.05
-1.05x market volatility
Max Drawdown
-29.4%
Largest decline past year
52-Week Range
$394-$615
Price range past year
Annual Return
+2.4%
Cumulative gain past year
| Period | MDGL Return | S&P 500 |
|---|---|---|
| 1m | -15.4% | -1.0% |
| 3m | -20.3% | +2.9% |
| 6m | -15.3% | +6.5% |
| 1y | +2.4% | +13.1% |
| ytd | -26.9% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDGL Fundamental Analysis
Revenue is growing rapidly but decelerating at the margin: Q2 2026 revenue of $364.25 million rose 71.17% year-over-year versus $212.80 million in Q2 2025, while sequential growth from Q1 2026's $311.34 million was a more modest 17.0%. The multi-quarter trajectory shows revenue climbing from $287.27 million in Q3 2025 to $321.08 million in Q4 2025, $311.34 million in Q1 2026, and $364.25 million in Q2 2026, a generally upward path with some quarterly lumpiness. With a single reportable segment and Rezdiffra as the sole commercial product, growth is entirely dependent on MASH launch penetration, and the 71% YoY rate implies the investment case still rests on rapid adoption rather than a mature, predictable revenue base.
Madrigal remains unprofitable, with Q2 2026 net income of -$57.94 million and an EPS of -$1.99, though the loss narrowed sharply from -$94.39 million (-$3.25) in Q1 2026 and -$114.19 million (-$5.08) in Q3 2025. Gross margin is exceptionally high at 89.02% in Q2 2026 (down from 91.38% in Q1 and 93.69% in Q3 2025), consistent with a specialty pharmaceutical cost structure, but operating margin of -31.31% reflects heavy SG&A of $289.38 million and R&D of $91.18 million in the quarter. The narrowing loss trajectory is encouraging, yet the sequential gross margin compression from 93.7% to 89.0% over three quarters warrants monitoring as a potential signal of pricing pressure or product mix/cost dynamics.
Balance-sheet health is solid: the current ratio stands at 4.01, debt-to-equity is a manageable 0.59, and cash at the end of Q2 2026 was $292.88 million, up from $232.19 million at the start of the quarter. However, free cash flow is negative at -$206.29 million on a trailing-twelve-month basis, and ROE of -47.83% and ROA of -17.84% confirm the company is still consuming capital. Q2 2026 operating cash flow turned positive at $23.33 million (versus -$167.44 million in Q1 2026), a meaningful inflection, but the volatile working-capital swings (inventory build of $11.46 million, receivables of $4.96 million) mean internal cash generation is not yet reliable enough to fully fund growth without the cushion of the investment portfolio.
Quarterly Revenue
$364252000.0B
2026-06
Revenue YoY Growth
+71.2%
YoY Comparison
Gross Margin
89.0%
Latest Quarter
Free Cash Flow
$-206285000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDGL Overvalued?
Because Madrigal's trailing net income is negative (EPS of -$0.02 on a normalized basis, trailing PE of -45.32x), the PE ratio is not meaningful; I therefore lead with the price-to-sales ratio of 13.63x and the EV/Sales multiple of 7.89x as the primary valuation anchors. The forward PE of 46.73x is the critical data point: it implies the market expects a dramatic swing to profitability, with consensus estimated EPS of $55.99 and estimated revenue of $4.80 billion, a gap that prices in substantial operating leverage over the next twelve to twenty-four months. The PEG ratio of 1.10 suggests that, on growth-adjusted terms, the valuation is not stretched relative to expected earnings expansion.
Against the biotechnology sector, the 13.63x PS multiple is a premium to typical commercial-stage biotech levels, though the comparison is imperfect given Madrigal's 71% revenue growth and 89% gross margin. The 21.68x price-to-book ratio is elevated and reflects the asset-light, IP-driven nature of the business rather than tangible book value. The premium is arguably justified by Rezdiffra's first-mover position in MASH and the steep revenue ramp, but it leaves little room for execution missteps, and the negative EV/EBITDA of -49.99x confirms the company has not yet crossed into profitability.
Historically, Madrigal's PS ratio has compressed dramatically as revenue scaled: from 42.96x in Q2 2026's reported historical ratios and 48.81x in Q1 2026 down to the current 13.63x, and from over 400x in mid-2024 when revenue was minimal. This compression reflects revenue growth outpacing share-price gains, which is a healthier dynamic than multiple expansion, but the stock's PB ratio of 21.68x is near the upper end of its recent band (versus 16.48x in Q3 2025 and 9.66x in Q2 2025), suggesting the market is still assigning a rich premium to book. The current valuation sits in a middle zone: cheaper than its own history on sales but expensive on book and dependent on the forward earnings inflection materializing.
PE
-45.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-50.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Madrigal remains unprofitable with a Q2 2026 net loss of -$57.94 million and trailing twelve-month free cash flow of -$206.29 million, consuming capital despite $292.88 million in cash. The company's entire revenue ($364.25 million in Q2 2026) comes from a single product, Rezdiffra, creating concentration risk; any slowdown in MASH adoption or payer pushback would directly hit results. Additionally, gross margin has compressed from 93.7% in Q3 2025 to 89.0% in Q2 2026, and operating margin is -31.31%, reflecting heavy SG&A ($289.38 million) and R&D ($91.18 million) spending that must be absorbed by future revenue growth.
Market and competitive risks are elevated. The stock trades at a premium valuation (13.63x PS, 21.68x PB, 46.73x forward PE) that assumes a dramatic profitability inflection; any disappointment could trigger severe multiple compression. The beta of -1.052 is unusual and implies the stock has historically moved inversely to the market, complicating hedging and position sizing. Competitive threats in MASH are emerging, and the recent share price weakness (-24.27% YTD, -15.0% in one month) reflects growing skepticism about long-term growth durability. Sector rotation away from high-multiple biotech could exacerbate downside.
Worst-case scenario: If Rezdiffra growth decelerates sharply, payer access tightens, or a competitor gains traction, the stock could retest its 52-week low of $393.61, representing a 12.5% decline from the current $449.74. A more severe selloff to the analyst low target of $543.00 is actually above current price, but if sentiment deteriorates further, the stock could fall below the 52-week low toward $350, implying a 22% loss. The maximum drawdown of -29.36% suggests that a decline of 30% from current levels (to ~$315) is within historical precedent, equating to a loss of roughly $135 per share.
FAQ
The key risks are: 1) Financial risk: the company is unprofitable with a net loss of -$57.94 million in Q2 2026 and negative free cash flow of -$206.29 million TTM, requiring continued capital. 2) Competitive risk: Rezdiffra faces potential competition in the MASH market, and any superior therapy could erode its first-mover advantage. 3) Valuation risk: the premium multiples (13.63x PS, 46.73x forward PE) leave little room for disappointment, and any growth deceleration could trigger multiple compression. 4) Macro risk: the negative beta of -1.052 means the stock may not hedge market downturns, and biotech sector rotation could exacerbate volatility. Ranked by severity: valuation and financial risks are highest, followed by competitive and macro risks.
The 12-month forecast has three scenarios: Bull case (30% probability) with a target range of $685-$962, driven by revenue growth above 60% YoY and an earlier path to profitability. Base case (50% probability) with a target range of $543-$686, assuming revenue growth moderates to 40-50% YoY and the company remains on track to profitability. Bear case (20% probability) with a target range of $393-$543, if revenue growth slows below 30% YoY or competitive threats emerge. The base case is most likely, with the key assumption that revenue growth remains robust and operating cash flow turns sustainably positive by mid-2027.
MDGL appears fairly valued relative to its growth prospects, but with a premium. The PS ratio of 13.63x is elevated for a commercial-stage biotech, but the 71% revenue growth and 89% gross margin justify some premium. The forward PE of 46.73x implies the market expects a dramatic swing to profitability, with consensus EPS of $55.99. The PEG ratio of 1.10 suggests the valuation is reasonable on a growth-adjusted basis. However, the stock is expensive on book (21.68x PB) and has little room for error. Compared to its own history, the PS ratio has compressed from over 400x in mid-2024 to 13.63x, reflecting revenue growth outpacing share price gains.
From a risk/reward perspective, MDGL is a Hold rather than a Buy. The stock offers 52.5% upside to the analyst average target of $685.78, but it is in a severe downtrend (-24.27% YTD) and trades at a premium valuation (13.63x PS, 46.73x forward PE). The biggest downside risk is a retest of the 52-week low of $393.61, representing a 12.5% decline. It could be a good buy for long-term investors who believe in the MASH opportunity and can tolerate volatility, but only after the stock shows signs of stabilization and revenue growth proves sustainable.
MDGL is more suitable for long-term investment (minimum 2-3 years) given its growth stage, negative earnings, and high volatility (beta -1.052, max drawdown -29.36%). The company does not pay dividends, and earnings visibility is limited due to its single-product dependence. Short-term trading is risky due to the strong downtrend and negative momentum. Investors should be prepared for significant price swings and should focus on the commercial execution of Rezdiffra and the path to profitability. A suggested minimum holding period is 2-3 years to allow for the MASH market to mature and for the company to achieve sustainable profitability.